CHICAGO–([SBP])–Proteus Digital Health presented interim results from a randomized
controlled study of Proteus Discover for patients with uncontrolled
hypertension and type 2 diabetes at the 65th Annual American College of
Cardiology meeting. Proteus Discover, a digital medicine offering,
consists of sensor-enabled medicines, a small wearable sensor patch.
applications for patients and clinical care givers. Proteus Discover
directly measures medication-taking and physiology to support patient
self-management and helps physicians and their care teams optimise
therapy. This study builds upon evidence gained through 66 studies
across diverse patient populations to assess accuracy, safety.
feasibility of use of Proteus Discover in patients with diseases such as
hypertension and diabetes.
Patients with uncontrolled hypertension, diabetes.
hypercholesterolemia are at high-risk for cardiovascular events and
costly interventions. Controlling these diseases has been shown to
reduce the risk of these complications.1,2 Nearly half of
patients with hypertension and type 2 diabetes fail to achieve treatment
goals. Medication non-adherence, poor patient engagement. Lack of
treatment optimization are major reasons for patients failing to achieve
their treatment goals.3-8The study enrolled
patients with these risk factors to understand whether a digital health
offering including digital medicines improves clinical outcomes and
This interim analysis revealed that patients with uncontrolled
hypertension and diabetes who used Proteus Discover achieved
statistically greater reduction in blood pressure (BP) and low-density
lipoprotein-cholesterol (LDL), known risk factors for cardiovascular
events. Were more likely to achieve their BP goal than usual care.
“The promising results from the pilot study demonstrate that this
innovative digital approach to therapy optimisation isn't only
patient-centered. Can lead to improved clinical outcomes,” said
George Savage, Chief Medical Officer of Proteus Digital Health. “The
findings suggest that deploying a panel of medicines that reflect the
needs of patients and physicians can move the needle in treatment
In this 12-week, IRB-approved study, 96 patients (mean age 58; 50% male)
were enrolled with uncontrolled hypertension (systolic blood pressure
[SBP] ≥140 mm Hg) and type 2 diabetes (A1C ≥7%) who'd failed at least
two anti-hypertensive medications plus metformin and/or sulfonylurea.
Subjects received Proteus Discover for 4 or 12 weeks. usual care
based on a cluster randomized study design. The primary outcome was
change in SBP at week 4. Secondary outcomes included change in diastolic
blood pressure and proportion of subjects at BP target (
Proteus Digital Health
Robin Suchan, +1 650-637-6221